Role of NADPH-cytochrome P450 reductase and cytochrome-b 5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes

Drug Metabolism and Disposition

Volumn 37, Issue 1, 2009, Pages 90-96

  Gan, Lu ^a   Von Moltke, Lisa L ^a   Trepanier, Lauren A ^b   Harmatz, Jerold S ^a   Greenblatt, David J ^a   Court, Michael H ^a,c  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME B5; CYTOCHROME P450 3A; PROPYLTHIOURACIL; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; THIOCTIC ACID; TRIAZOLAM;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROXYLATION; IMMUNOBLOTTING; LIVER MICROSOME; MALE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; SPECTROPHOTOMETRY;

AGING; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROME-B(5) REDUCTASE; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; NADPH-FERRIHEMOPROTEIN REDUCTASE; SEX FACTORS; THIOCTIC ACID;

EID: 58149472378     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023424     Document Type: Article

References (35)

1. Badwey JA, Tauber AI, and Karnovsky ML (1983) Properties of NADH-cytochrome-b5 reductase from human neutrophils. Blood 62:152-157.
2. Cotreau MM, von Moltke LL, and Greenblatt DJ (2005) The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44:33-60.
3. Dudka J (2006) Decrease in NADPH-cytochrome P450 reductase activity of the human heart Liver and lungs in the presence of alpha-lipoic acid. Ann Nutr Metab 50:121-125.
4. Elmore CL and Porter TD (2002) Modification of The uucleotide cofactor-binding site of cytochrome P-450 reductase to enhance turnover with NADH in vivo. J Biol Chem 277: 48960-48964.
5. George J, Byth K, and Farrell GC (1995) Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 50:727-730.
6. Guengerich FP (2005) Reduction of cytochrome b5 by NADPH-cytochrome P450 reductase. Arch Biochem Biophys 440:204-211.
7. Guo Z, Wang M, Tian G, Burger J, Gochfeld M, and Yang CS (1993) Age- and gender-related variations in the activities of drug-metabolizing and antioxidant enzymes in the white-footed mouse (Peromvscus leucopus). Growth Dev Aging 57:85-100.
8. He P, Court MH, Greenblatt DJ, and von Moltke LL (2006) Factors influencing midazolam hydroxy lation activity in human liver microsomes. Drug Metab Dispos 34:1198-1207.
9. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, and Court MH (2004) Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharniacogenetics 14:225-238.
10. Holmans PL, Shet MS, Marfin-Wixtrom CA, Fisher CW, and Estabrook RW (1994) The high-level expression in Escherichia coli of the membrane-bound form of human and rat cytochrome b5 and studies on their mechanism of function. Arch Biochem Biophvs 312:554-565.
11. Kurian JR, Bajad SU, Miller JL, Chin NA, and Trepanier LA (2004) NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J Pharmacol Exp Ther 311:1171-1178.
12. Lee E and Kariya K (1986) Propylthiouracil, a selective inhibitor of NADH-cytochrome b5 reductase. FEBS Lett 209:49-51.
13. Maloney AG, Schmucker DL, Vessey DS, and Wang RK. (1986) The effects of aging on the hepatic microsomal mixed-function oxidase system of male and female monkeys. Hepatology 6:282-287.
14. Matsuki T, Tamura M, Takeshita M, and Yoneyama Y (1981) Age-dependent decay of cytochrome b5 and cytochrome b5 reductase in human erythrocytes. J Biochem 194:327-330.
15. Murataliev MB, Feyereisen R, and Walker FA (2004) Electron transfer by diflavin reductases. Biochim Biophys Acta 1698:1-26.
16. Parkinson A, Mudra DR, Johnson C, Dwyer A, and Carroll KM (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199: 193-209.
17. Patki KC, von Moltke LL, Harmatz JS, Hesse LM, Court MH, and Greenblatt DJ (2004) Effect of age on in vitro triazolam biotransformation in male human liver microsomes. J Pharmacol Exp Ther 308:874-879.
18. Porter TD and Kasper CB (1986) NADPH-cytochrome P-450 oxidoreductase: flavin mononucleotide and flavin adenine dinucleotide domains evolved from different flavoproteins. Biochemistry 25:1682-1687.
19. Schmucker DL and Wang RK (1983) Age-dependent alterations in rat liver microsomal NADPH-cytochrome c (P-450) reductase: a qualitative and quantitative analysis. Mech Ageing Dev 21:137-156.
20. Schmucker DL and Wang RK (1987) Effects of aging on the properties of rhesus monkey liver microsomal NADPH-cytochrome c (P-450) reductase. Drug Merab Dispos 15:225-232.
21. Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, McManus M, and Kremers P (1990) Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 48:365-374.
22. Shephard EA, Palmer CN, Segall HJ, and Phillips IR (1992) Quantification of cytochrome P450 reductase gene expression in human tissues. Arch Biochem Biophys 294:168-172.
23. Simmons DL and Kasper CB (1989) Quantitation of mRNAs specific for the mixed-function oxidase system in rat liver and extrahepatic tissues during development. Arch Biochem Biophys 271:10-20.
24. Slepneva IA, Sergeeva SV, and Khramtsov VV (1995) Reversible inhibition of NADPH-cytochrome P450 reductase by alpha-lipoic acid. Biochem Biophys Res Commun 214:1246-1253.
25. Streetman DD and Khanderia U (2003) Diagnosis and treatment of Graves disease. Ann Pharmacother 37:1100-1109.
26. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
27. Vergéres G and Waskell L (1995) Cytochrome b5, its functions, structure and membrane topology. Biochimie 77:604-620.
28. Voice MW, Zhang Y, Wolf CR, Burchell B, and Friedberg T (1999) Effects of human cytochrome b5 on CYP3A4 activity and stability in vivo. Arch Biochem Biophvs 366:116-124.
29. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, and Shader RI (1996) Triazolam hiotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
30. von Moltke LL, Greenblatt DJ, Harmatz JS, and Shader RI (1993) Alprazolam metabolism in vitro: studies of human, monkey, mouse and rat liver microsomes. Pharmacology 47:268-276.
31. Warrington JS, Greenblatt DJ, and von Moltke LL (2004) Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney. J Phannacol Exp Ther 309: 720-729.
32. Yamazaki H, Nakajima M, Nakamura M, Asahi S, Shimada N, Gillam EM, Guengerich FP, Shimada T, and Yokoi T (1999) Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes. Drug Metab Dispos 27:999-1004.
33. Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M, et al. (2002) Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif 24:329-337.
34. Yamazaki H, Nakano M, Imai Y, Ueng YF, Guengerich FP, and Shimada T (1996) Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch Biochem Biophys 325:174-182.
35. Yelinova VI, Weiner LM, Slepneva 1A, and Levina AS (1993) Reversible modification of cysteine residues of NADPH-cytochrome P-450 reductase. Biochem Biophys Res Commun 193:1044-1048.